From hydralazine to CGRP to man?

S. B. Field, I. A. Burney, S. Needham, R. J. Maxwell, J. R. Griffiths

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Attempts to selectively reduce tumour blood flow have, in the past, concentrated on the use of hydralazine. However, although this vasodilator can be highly effective in experimental animals, it is only at such high concentration as to result in a severe and clinically unacceptable reduction in systemic blood pressure. At clinically acceptable levels, the drug appears to produce a small increase in tumour blood flow. We have used the techniques of magnetic resonance spectroscopy as indicators of metabolism and blood flow in a search for vasoactive drugs that would produce an effective reduction in tumour blood flow without causing severe hypotension or other serious side effects. Single injections of either prazosin or CGRP are shown to be substantially more effective than hydralazine in causing a reduction in tumour blood flow without massive reduction in blood pressure. Even more effective was CGRP given by continuous infusion. In this case a three-fold reduction in tumour blood flow could be obtained with a reduction of only 15-20% in systemic blood pressure. All these studies, however, have been made with transplanted animal tumours. Using high-dose hydralazine and primary tumours that were either radiation or chemically induced, we obtained a success rate of only about a 35% in causing selective reduction in blood flow. In contrast, in a transplanted tumour line derived from one of the non-responding radiation-induced primary lesions, the success rate was about 95% consistent with the majority of animal studies using transplanted tumours. An implication of this finding is that the results of vascular studies on transplanted tumours may not necessarily be extrapolated directly to spontaneous tumours. Whether or not this is the case for CGRP needs to be investigated in man.

Original languageEnglish
Pages (from-to)451-455
Number of pages5
JournalInternational Journal of Hyperthermia
Volume10
Issue number3
DOIs
Publication statusPublished - 1994

Fingerprint

Hydralazine
Neoplasms
Blood Pressure
Radiation
Prazosin
Vasodilator Agents
Pharmaceutical Preparations
Hypotension
Blood Vessels
Magnetic Resonance Spectroscopy

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Physiology (medical)
  • Cancer Research
  • Physiology

Cite this

Field, S. B., Burney, I. A., Needham, S., Maxwell, R. J., & Griffiths, J. R. (1994). From hydralazine to CGRP to man? International Journal of Hyperthermia, 10(3), 451-455. https://doi.org/10.3109/02656739409010291

From hydralazine to CGRP to man? / Field, S. B.; Burney, I. A.; Needham, S.; Maxwell, R. J.; Griffiths, J. R.

In: International Journal of Hyperthermia, Vol. 10, No. 3, 1994, p. 451-455.

Research output: Contribution to journalArticle

Field, SB, Burney, IA, Needham, S, Maxwell, RJ & Griffiths, JR 1994, 'From hydralazine to CGRP to man?', International Journal of Hyperthermia, vol. 10, no. 3, pp. 451-455. https://doi.org/10.3109/02656739409010291
Field, S. B. ; Burney, I. A. ; Needham, S. ; Maxwell, R. J. ; Griffiths, J. R. / From hydralazine to CGRP to man?. In: International Journal of Hyperthermia. 1994 ; Vol. 10, No. 3. pp. 451-455.
@article{3ca3bad6145f47a4b21015bc9b324244,
title = "From hydralazine to CGRP to man?",
abstract = "Attempts to selectively reduce tumour blood flow have, in the past, concentrated on the use of hydralazine. However, although this vasodilator can be highly effective in experimental animals, it is only at such high concentration as to result in a severe and clinically unacceptable reduction in systemic blood pressure. At clinically acceptable levels, the drug appears to produce a small increase in tumour blood flow. We have used the techniques of magnetic resonance spectroscopy as indicators of metabolism and blood flow in a search for vasoactive drugs that would produce an effective reduction in tumour blood flow without causing severe hypotension or other serious side effects. Single injections of either prazosin or CGRP are shown to be substantially more effective than hydralazine in causing a reduction in tumour blood flow without massive reduction in blood pressure. Even more effective was CGRP given by continuous infusion. In this case a three-fold reduction in tumour blood flow could be obtained with a reduction of only 15-20{\%} in systemic blood pressure. All these studies, however, have been made with transplanted animal tumours. Using high-dose hydralazine and primary tumours that were either radiation or chemically induced, we obtained a success rate of only about a 35{\%} in causing selective reduction in blood flow. In contrast, in a transplanted tumour line derived from one of the non-responding radiation-induced primary lesions, the success rate was about 95{\%} consistent with the majority of animal studies using transplanted tumours. An implication of this finding is that the results of vascular studies on transplanted tumours may not necessarily be extrapolated directly to spontaneous tumours. Whether or not this is the case for CGRP needs to be investigated in man.",
author = "Field, {S. B.} and Burney, {I. A.} and S. Needham and Maxwell, {R. J.} and Griffiths, {J. R.}",
year = "1994",
doi = "10.3109/02656739409010291",
language = "English",
volume = "10",
pages = "451--455",
journal = "International Journal of Hyperthermia",
issn = "0265-6736",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - From hydralazine to CGRP to man?

AU - Field, S. B.

AU - Burney, I. A.

AU - Needham, S.

AU - Maxwell, R. J.

AU - Griffiths, J. R.

PY - 1994

Y1 - 1994

N2 - Attempts to selectively reduce tumour blood flow have, in the past, concentrated on the use of hydralazine. However, although this vasodilator can be highly effective in experimental animals, it is only at such high concentration as to result in a severe and clinically unacceptable reduction in systemic blood pressure. At clinically acceptable levels, the drug appears to produce a small increase in tumour blood flow. We have used the techniques of magnetic resonance spectroscopy as indicators of metabolism and blood flow in a search for vasoactive drugs that would produce an effective reduction in tumour blood flow without causing severe hypotension or other serious side effects. Single injections of either prazosin or CGRP are shown to be substantially more effective than hydralazine in causing a reduction in tumour blood flow without massive reduction in blood pressure. Even more effective was CGRP given by continuous infusion. In this case a three-fold reduction in tumour blood flow could be obtained with a reduction of only 15-20% in systemic blood pressure. All these studies, however, have been made with transplanted animal tumours. Using high-dose hydralazine and primary tumours that were either radiation or chemically induced, we obtained a success rate of only about a 35% in causing selective reduction in blood flow. In contrast, in a transplanted tumour line derived from one of the non-responding radiation-induced primary lesions, the success rate was about 95% consistent with the majority of animal studies using transplanted tumours. An implication of this finding is that the results of vascular studies on transplanted tumours may not necessarily be extrapolated directly to spontaneous tumours. Whether or not this is the case for CGRP needs to be investigated in man.

AB - Attempts to selectively reduce tumour blood flow have, in the past, concentrated on the use of hydralazine. However, although this vasodilator can be highly effective in experimental animals, it is only at such high concentration as to result in a severe and clinically unacceptable reduction in systemic blood pressure. At clinically acceptable levels, the drug appears to produce a small increase in tumour blood flow. We have used the techniques of magnetic resonance spectroscopy as indicators of metabolism and blood flow in a search for vasoactive drugs that would produce an effective reduction in tumour blood flow without causing severe hypotension or other serious side effects. Single injections of either prazosin or CGRP are shown to be substantially more effective than hydralazine in causing a reduction in tumour blood flow without massive reduction in blood pressure. Even more effective was CGRP given by continuous infusion. In this case a three-fold reduction in tumour blood flow could be obtained with a reduction of only 15-20% in systemic blood pressure. All these studies, however, have been made with transplanted animal tumours. Using high-dose hydralazine and primary tumours that were either radiation or chemically induced, we obtained a success rate of only about a 35% in causing selective reduction in blood flow. In contrast, in a transplanted tumour line derived from one of the non-responding radiation-induced primary lesions, the success rate was about 95% consistent with the majority of animal studies using transplanted tumours. An implication of this finding is that the results of vascular studies on transplanted tumours may not necessarily be extrapolated directly to spontaneous tumours. Whether or not this is the case for CGRP needs to be investigated in man.

UR - http://www.scopus.com/inward/record.url?scp=0028287270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028287270&partnerID=8YFLogxK

U2 - 10.3109/02656739409010291

DO - 10.3109/02656739409010291

M3 - Article

VL - 10

SP - 451

EP - 455

JO - International Journal of Hyperthermia

JF - International Journal of Hyperthermia

SN - 0265-6736

IS - 3

ER -